Skip to main content
. Author manuscript; available in PMC: 2008 May 5.
Published in final edited form as: AIDS. 2007 May 11;21(8):973–982. doi: 10.1097/QAD.0b013e328011ec53

Fig. 2. The incremental cost-effectiveness of non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (versus cotrimoxazole prophylaxis only) and boosted protease inhibitor (PI)-based (versus NNRTI-based) regimens at various prevalence rates of NNRTI resistance and boosted PI regimen costs.

Fig. 2

Only one regimen of antiretroviral therapy is available in this analysis. The cost-effectiveness threshold of three times the gross domestic product in Côte d’Ivoire ($2409) is indicated by the dotted horizontal line.